BR112016024749A2 - composto, composição farmacêutica, e, método de tratamento de câncer, de um distúrbio inflamatório, de um distúrbio de autoimunidade ou de um distúrbio neurodegenerativo - Google Patents

composto, composição farmacêutica, e, método de tratamento de câncer, de um distúrbio inflamatório, de um distúrbio de autoimunidade ou de um distúrbio neurodegenerativo

Info

Publication number
BR112016024749A2
BR112016024749A2 BR112016024749A BR112016024749A BR112016024749A2 BR 112016024749 A2 BR112016024749 A2 BR 112016024749A2 BR 112016024749 A BR112016024749 A BR 112016024749A BR 112016024749 A BR112016024749 A BR 112016024749A BR 112016024749 A2 BR112016024749 A2 BR 112016024749A2
Authority
BR
Brazil
Prior art keywords
disorder
compound
pharmaceutical composition
treating cancer
neurodegenerative
Prior art date
Application number
BR112016024749A
Other languages
English (en)
Portuguese (pt)
Inventor
Liberg David
Hargrave Jonathan
EKBLAD Maria
Bainbridge Marie
Prevost Natacha
East Stephen
Wellmar Ulf
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Publication of BR112016024749A2 publication Critical patent/BR112016024749A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cosmetics (AREA)
BR112016024749A 2014-05-23 2015-05-22 composto, composição farmacêutica, e, método de tratamento de câncer, de um distúrbio inflamatório, de um distúrbio de autoimunidade ou de um distúrbio neurodegenerativo BR112016024749A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14169757 2014-05-23
PCT/EP2015/061468 WO2015177367A1 (en) 2014-05-23 2015-05-22 Novel compounds useful as s100-inhibitors

Publications (1)

Publication Number Publication Date
BR112016024749A2 true BR112016024749A2 (pt) 2017-08-15

Family

ID=50774707

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016024749A BR112016024749A2 (pt) 2014-05-23 2015-05-22 composto, composição farmacêutica, e, método de tratamento de câncer, de um distúrbio inflamatório, de um distúrbio de autoimunidade ou de um distúrbio neurodegenerativo

Country Status (12)

Country Link
US (1) US9771372B2 (enExample)
EP (1) EP2991990B1 (enExample)
JP (1) JP6580074B2 (enExample)
KR (1) KR20170005868A (enExample)
CN (1) CN106414448B (enExample)
AU (1) AU2015261775B2 (enExample)
BR (1) BR112016024749A2 (enExample)
CA (1) CA2948436A1 (enExample)
EA (1) EA030604B1 (enExample)
ES (1) ES2620751T3 (enExample)
MX (1) MX2016014483A (enExample)
WO (1) WO2015177367A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019208290A1 (ja) 2018-04-27 2019-10-31 国立大学法人 岡山大学 抗ｓ１００ａ８／ａ９抗体とその用途
US11197908B2 (en) 2018-07-17 2021-12-14 The Board Of Trustees Of The University Of Arkansas Peptoids and methods for attenuating inflammatory response
WO2021085252A1 (ja) 2019-10-30 2021-05-06 国立大学法人 岡山大学 炎症性肺疾患の予防及び／又は治療剤
WO2023209141A1 (en) 2022-04-29 2023-11-02 Westfälische Wilhelms-Universität Münster Benzo[d]imidazo[1,2-a]imidazoles and their use in diagnosis
WO2025132458A1 (en) 2023-12-18 2025-06-26 Chiesi Farmaceutici S.P.A. Pyridazinyl amino derivatives as alk5 inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248755B1 (en) 1999-04-06 2001-06-19 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
AR029489A1 (es) 2000-03-10 2003-07-02 Euro Celtique Sa Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
IL154107A0 (en) 2000-07-26 2003-07-31 Smithkline Beecham Plc Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
JP2004523565A (ja) * 2001-03-05 2004-08-05 トランス　テック　ファーマ，インコーポレイテッド 治療因子としてのベンゾイミダゾール誘導体
GB0117506D0 (en) 2001-07-18 2001-09-12 Bayer Ag Imidazopyridinones
SE0104331D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Novel compounds
ATE529110T1 (de) * 2002-03-05 2011-11-15 Transtech Pharma Inc Mono- und bicyclische azolderivate die die interaktion von liganden mit rage hemmen
US20060111416A1 (en) 2004-11-24 2006-05-25 Lane Charlotte A L Octahydropyrrolo[3,4-C]pyrrole derivatives
JP2010504980A (ja) 2006-09-28 2010-02-18 エグゼリクシス， インコーポレイテッド Ｊａｋ−２モジュレーターおよび使用方法
EP2132207A2 (en) 2007-03-23 2009-12-16 Amgen Inc. Heterocyclic compounds and their uses
EP1986009A1 (en) * 2007-04-26 2008-10-29 Active Biotech AB Screening method
EP2170072A4 (en) 2007-06-13 2010-10-27 Glaxosmithkline Llc Farnesoid X RECEPTOR AGONISTS
US8785460B2 (en) * 2008-01-22 2014-07-22 Takeda Pharmaceutical Company Limited Tricyclic compounds and use thereof
TW201004941A (en) 2008-07-16 2010-02-01 Wyeth Corp Alpha7 nicotinic acetylcholine receptor inhibitors
CN102414180A (zh) 2009-03-02 2012-04-11 西特里斯药业公司 作为沉默调节蛋白调节剂的8-取代的喹啉及相关的类似物
KR20140096100A (ko) 2011-11-03 2014-08-04 에프. 호프만-라 로슈 아게 이환 피페라진 화합물
GB201321728D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents

Also Published As

Publication number Publication date
HK1221463A1 (en) 2017-06-02
EP2991990B1 (en) 2017-02-01
EA030604B1 (ru) 2018-08-31
US20170204098A1 (en) 2017-07-20
CA2948436A1 (en) 2015-11-26
MX2016014483A (es) 2017-01-23
WO2015177367A1 (en) 2015-11-26
JP6580074B2 (ja) 2019-09-25
JP2017516772A (ja) 2017-06-22
CN106414448A (zh) 2017-02-15
EP2991990A1 (en) 2016-03-09
AU2015261775B2 (en) 2019-07-11
CN106414448B (zh) 2019-04-19
US9771372B2 (en) 2017-09-26
AU2015261775A1 (en) 2016-12-08
KR20170005868A (ko) 2017-01-16
EA201692405A1 (ru) 2017-06-30
ES2620751T3 (es) 2017-06-29

Similar Documents

Publication Publication Date Title
JOP20190194A1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
CL2015002658A1 (es) Derivados de 2, 3 - disustituto 1- acil -4 amino - 1,2,3,4 tetrahidroquinilina y su uso como inhibidores de bromodominio
DOP2017000048A (es) Compuestos aminopirimidinilo como inhibidores de jak.
UY37018A (es) Inhibidores bicíclicos de pad4
MX2018013983A (es) Inhibidores g12c de kras.
MX2016002137A (es) Ciertas entidades quimicas, composiciones y metodos.
MX381640B (es) Metodos y compuestos agonistas de gip.
EA201790528A1 (ru) Дигидропирролопиридиновые ингибиторы ror-гамма
PH12017500509A1 (en) Benzyl substituted indazoles as bub1 inhibitors
NI201600071A (es) Compuestos de inhibidor de autotaxina
MX2018006578A (es) Formulaciones farmaceuticas topicas para tratar afecciones inflamatorias.
EA201691516A1 (ru) Дигидропирролопиридиновые ингибиторы ror-гамма
EA201591509A1 (ru) Ингибиторы cdc7
MX381046B (es) Anticuerpos anti-csf1r e inhibidores de pd-1/pd-l1, y usos de los mismos para el tratamiento de cáncer remisión a las solicitudes relacionadas.
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
EA201692091A1 (ru) Хиноксалиновые соединения и их применение
MX2017016322A (es) Metodos para tratar tumores de celulas epitelioides.
UY37017A (es) Inhibidores aza-bencimidazol de pad4
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
CL2016000326A1 (es) Composiciones y método para tratar condiciones asociadas con el complemento
JO3668B1 (ar) مركبات بلاديينوليد البيريدين وطرق استعمالها
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
EA201690783A1 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
UY34615A (es) Nuevos compuestos útiles para el tratamiento de enfermedades degenerativas e inflamatorias.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2622 DE 06-04-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.